

## **Natural immunity against COVID-19 significantly reduces the risk of reinfection: findings from a cohort of sero-survey participants**

Bijaya Kumar Mishra, MD, Debdutta Bhattacharya, PhD, Jaya Singh Kshatri, MD Sanghamitra Pati,  
MD, MPH \*

ICMR-Regional Medical Research Centre (Dept. of Health Research, Ministry of Health & Family  
Welfare, Govt. of India), Bhubaneswar-751023, Odisha, India

**\*Address for correspondence** : **Dr. Sanghamitra Pati**  
Scientist-G & Director  
ICMR-Regional Medical Research Centre,  
(Dept. of Health Research, Ministry of  
Health & Family Welfare, Govt. of India),  
Chandrasekharpur, Bhubaneswar-  
751023  
[drsanghamitra12@gmail.com](mailto:drsanghamitra12@gmail.com)

**Phone Number** : +91 674 2305655

**Fax Number** : +91 674 2301351

**Keyword** : COVID-19; sero survey; natural immunity;  
sero-positive; sero-negative

## **Abstract:**

Conflicting reports on the persistence of antibody levels in individuals recovered from COVID-19 infection, suggest that the immunity against COVID-19 may not be lasting for long. In India, by 30th June, 2021, not less than 30 million people were infected with COVID-19 and 0.39 million people were reported to have lost their life to the disease in India. In the current study we followed up with a subsample of our previous sero-survey participants to assess whether natural immunity against SARS-CoV-2 was associated with a reduced risk of re-infection. We conducted telephonic interview of a total of 3038 participants, out of which 2238 participants responded and 5 participants were found to be not alive, as conveyed by their close relatives. There was a non-response rate of 26.1%. Out of the 2238 participants, 1170 were sero-positive and 1068 were sero-negative for antibody against COVID-19. Our survey found that only 3 individuals in the sero-positive group got infected with COVID-19 whereas 127 individuals reported contracting the infection in the sero-negative group. Interestingly, from the 127 sero-negative individuals who later contracted COVID-19 infection, 30 needed hospitalization, out of which 12 were on oxygen therapy, four in ICU and one was on ventilator. At the other hand, from the 3 sero-positives re-infected with COVID-19, one had hospitalization, but did not require oxygen support or critical care. These findings reinforce the strong plausibility that development of antibody following natural infection not only protects against re-infection by the virus to a great extent, but also safeguards against progression to severe COVID-19 disease.

## **Introduction:**

We read with interest the communication by Poletti et al.,<sup>1</sup> where the authors conclude that adherence to hygiene protocols and the maintenance of universal masking remain necessary ingredients in a multipronged strategy for infection reduction. Conflicting reports on the persistence of antibody levels in individuals recovered from COVID-19 infection, suggest that the immunity against COVID-19 may not be lasting for long.<sup>2,3</sup> In India, by 30<sup>th</sup> June, 2021, not less than 30 million people were infected with COVID-19 and 0.39 million people were reported to have lost their life to the disease in India.<sup>4</sup> Three rounds of sero-survey in the state of Odisha have demonstrated an increasing trend of population level exposure to SARS-CoV-2.<sup>5</sup> We followed up with a subsample of our previous sero-survey participants to assess whether natural immunity against SARS-CoV-2 was associated with a reduced risk of re-infection.

## **Methodology:**

We conducted telephonic interview of a total of 3038 participants selected from our previous serosurvey cohort from different district of Odisha. Data was recorded in preformed questionnaire. Consent was obtained prior to their enrollment in the study.

## **Results & Discussion:**

Out of 3038 participants contacted over telephone, 2238 participants responded and 5 participants were found to be not alive, as conveyed by their close relatives. There was a non-response rate of 26.1%. Out of the 2238 participants, 1170 were sero-positive and 1068 were sero-negative for antibody against COVID-19. Our survey found that only 3 individuals in the sero-positive group got infected with COVID-19 whereas 127 individuals reported contracting the infection the sero-negative group. Taking into account a median follow-up duration of 258 days (66-319 days) and considering a CI of 95%, the incidence of COVID-19 among the sero-positive was 4.09 /1000 person-years [95% CI:0.84-11.94] while that among the sero-negative was 173.68 /1000 person-years [95% CI: 144.78-206.64], thus making a rate difference of -169.59 /1000 person-years (95% CI: -200.15 to -139.03) and a rate ratio of 0.023 (95% CI: 0.007-0.073). This suggests that antibody produced in response to natural infection with COVID-19 is likely to reduce the risk of COVID re-infection by 97.7%. This is congruent with another similar study reporting that previous infection with COVID-19 decreases the risk of re-infection by 84%, with the median duration of protection being 7 months.<sup>5</sup> Interestingly, from the 127 sero-negative individuals who later contracted COVID-19 infection, 30 needed hospitalization, out of which 12 were on oxygen therapy, four in ICU and one was on ventilator. At the other hand, from the 3 sero-positives re-infected with COVID-19, one had hospitalization, but didn't require oxygen support or critical care.

## **Conclusion:**

These findings reinforce the strong plausibility that development of antibody following natural infection not only protects against re-infection by the virus to a great extent,<sup>6</sup> but also safeguards against progression to severe COVID-19 disease. However, further follow up must continue to draw concrete inferences on the protection conferred by naturally developing immunity after COVID-19 infection and its ability to protect against other emerging variants of the virus. Till that time, it is

prudent to ensure adherence to COVID-19 preventive protocols in a large dense demography like India.

### **Data availability**

All data in the manuscript are available on request to the corresponding author.

### **Declaration of Competing Interest**

The authors have no competing interests in any form.

### **Authors Contributions**

SP designed the study. BKM, JSK & DB were responsible for data collection and analysis. SP, BKM, JSK & DB wrote the manuscript. All authors have read and approved the final manuscript.

### **Acknowledgement**

The authors gratefully acknowledge all the healthcare workers for their tireless dedication at each level to fight COVID-19 and for voluntarily participating in this cohort study. The authors are thankful to the Indian Council of Medical Research, New Delhi and Dept. of Health & Family Welfare, Govt. of Odisha for providing financial support for the study.

### **References:**

1. Poletti P, Tirani M, Cereda D, Guzzetta G, Trentini F, Marziano V, Toso C, Piatti A, Piccarreta R, Melegaro A, Andreassi A, Gramegna M, Ajelli M, Merler S. Seroprevalence of and risk factors associated with SARS-CoV-2 infection in Health Care Workers during the early COVID-19 Pandemic in Italy. *JAMA Netw Open*. 2021 Jul 1;4(7):e2115699.
2. Choudhary, H. R. *et al.* IgG antibody response against nucleocapsid and spike protein post-SARS-CoV-2 infection. *Infection* (2021). <https://doi.org/10.1007/s15010-021-01651-4>.
3. Seow, J. *et al.* Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. *Nat Microbiol* **5**, 1598–1607 (2020).
4. *Ministry of Health and Family Welfare, Government of India (COVID-19) Dashboard*. <https://www.mohfw.gov.in/>.
5. Kshatri, J. S. *et al.* Seroprevalence of SARS-CoV-2 in Bhubaneswar, India: findings from three rounds of community surveys. *Epidemiol. Infect.* **149**, e139 (2021).

6. Hall, V. J. *et al.* SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). *The Lancet* **397**, 1459–1469 (2021).